comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-12 09:11:52 - browse：273

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

hotspot

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Winners, losers from Medicare’s list of drugs subject to price talks

Medicare coverage of Wegovy, once blocked, now looks possible

What AAP's gender

Feds fine Medicare Advantage plans for overcharging members

Neuroscience startup Neumora files for IPO

leisure time

comprehensive

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Medicare details structure of new drug price negotiation program

Apellis safety probe of eye disease drug centers on injection needle

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In science, is the line between industry and academia shifting?

Medicare proposal to cover medical devices draws a mixed reaction

FDA advisers back CAR

Trump demands the U.S. pay no more for drugs than other countries … again

Diversity in medical illustrations gets boost from Chidiebere Ibe

explore

UCLA team creates talking throat patch for voice disorders

Why scientists need input from humanists on sensitive research

WuXi out of biotech trade group, U.S. and China relations to blame

In science, is the line between industry and academia shifting?

Radiation, mainstay of cancer treatment, begins a fade

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

hotspot

hotspot

focus